Research Scientist III
Danaher Corporation
Summary
The Research Scientist III is responsible for new NGS assay product development and on market product support. General duties include designing and conducting experiments, analyzing and interpreting results, followed by communicating those results to both internal and external groups.
Job description
This position reports to the Staff Scientist and is part of the Assay Development team located in Boulder, CO and will be an on-site role.
In this role, you will have the opportunity to:
- Develop new products using a combination of wet-lab and dry-lab skillsets
- Plan and conduct experiments, perform data analysis, and interpret results with minimal oversight
- Brainstorm creative solutions to solve outstanding problems and improve existing technologies
- Support on market Next Generation Sequencing (NGS) products as a subject matter expert
- Present experimental demonstrations of products at scientific conferences
The essential requirements of the job include:
- M.Sc. in a life sciences field or related discipline and 3+ years experience with NGS, or Ph.D. in a life sciences or related discipline with some NGS experience.
- Experience in wet-lab work preparing nucleic acids for NGS, and experience in dry-lab programming for NGS data analysis
- Foundational knowledge of human genetics and cancer biology
- Excellent oral and written communication skills, with the ability to clearly and efficiently summarize complex scientific topics
- Familiarity with Illumina sequencing technology
Travel, Motor Vehicle Record & Physical/Environment Requirements:
- Ability to occasionally lift, move or carry equipment up to 10lb
- Ability to frequently work in a laboratory environment for extended periods
- Ability to travel to other IDT sites or scientific conferences (< 5%)
It would be a plus if you also possess previous experience in:
- Python programming, machine learning methods, and NextFlow.
- Product development for the analysis of cancer genetics, developing gene expression phenotype classifiers for RNA-seq or NGS methods for methylation detection
- Loading and troubleshooting Illumina sequencers
Requirements
- M.Sc. in a life sciences field or related discipline and 3+ years experience with NGS, or Ph.D. in a life sciences or related discipline with some NGS experience.
- Experience in wet-lab work preparing nucleic acids for NGS, and experience in dry-lab programming for NGS data analysis
- Foundational knowledge of human genetics and cancer biology
- Excellent oral and written communication skills, with the ability to clearly and efficiently summarize complex scientific topics
- Familiarity with Illumina sequencing technology
- Ability to occasionally lift, move or carry equipment up to 10lb
- Ability to frequently work in a laboratory environment for extended periods
- Ability to travel to other IDT sites or scientific conferences (< 5%)
- Python programming, machine learning methods, and NextFlow.
- Product development for the analysis of cancer genetics, developing gene expression phenotype classifiers for RNA-seq or NGS methods for methylation detection
- Loading and troubleshooting Illumina sequencers
Benefits
- Health care program
- Paid time off
- Medical insurance
- Dental insurance
- Vision insurance
- 401(k)
- Bonus/incentive pay
Company overview
Danaher Corporation is a leading global science and technology innovator headquartered in Washington, D.C., specializing in biotechnology, life sciences, and diagnostics. Founded in 1984 by brothers Steven and Mitchell Rales, the company has evolved from its origins as a manufacturing conglomerate into a premier healthcare technology organization with approximately 63,000 employees worldwide. Danaher operates through three core divisions: biotechnology (28% of revenues), which develops products for therapeutic development; life sciences (31% of revenues), focused on disease identification, new therapies, and drug testing/manufacturing; and diagnostics (41% of revenues), providing instruments, consumables, and software for disease diagnosis. The company's portfolio includes renowned brands such as Beckman Coulter, Cytiva, Pall Corporation, Cepheid, Leica Microsystems, and Abcam, serving pharmaceutical companies, biotechnology firms, healthcare providers, and research institutions globally. Danaher is distinguished by its Danaher Business System (DBS), a continuous improvement methodology that drives innovation and operational excellence. With 2024 revenues of $23.9 billion, the company ranks 180th on the Fortune 500 and plays a critical role in advancing scientific research, improving diagnostic capabilities, and accelerating the development of life-saving therapies.